Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01443260
Recruitment Status : Completed
First Posted : September 29, 2011
Last Update Posted : March 10, 2015
Information provided by (Responsible Party):
Genelux Corporation ( Genelux GmbH )

Brief Summary:
The purpose of this study is to determine whether GL-ONC1, an attenuated vaccinia virus, is safe when administered to patients with peritoneal carcinomatosis via an infusion within the abdominal cavity through an implanted catheter. The study seeks also to arrive at a recommended dose and schedule for future investigations, evidence of anti-tumor activity, detection of virus in body fluids, analysis of viral delivery to tumor and normal cells, and to evaluate if there is an antibody response to vaccinia virus.

Condition or disease Intervention/treatment Phase
Peritoneal Carcinomatosis Biological: GL-ONC1 Phase 1 Phase 2

Detailed Description:
Peritoneal carcinomatosis includes a variety of tumors with extensive metastasis throughout the peritoneal cavity (inside surface of the abdomen) and can be found with gall bladder, liver, colon, appendix, ovarian, pancreas, mesothelioma, pseudomyxoma peritonei, rectal, small bowel and stomach cancers. It broadly includes multiple tumors that develop in and line the peritoneal abdominal cavity and linings. These tumors may be difficult to completely remove surgically and may recur despite conventional systemic chemotherapy, thereby resulting in poor patient outcomes. In preclinical studies, GL-ONC1, an oncolytic vaccinia virus, has shown the ability to preferentially locate, colonize and destroy tumor cells in more than 30 different human tumors. A Phase I clinical study focusing on the safety and tolerability of GL-ONC1 intravenously administered to patients with a variety of solid tumor entities has shown that GL-ONC1 is well-tolerated at therapeutic dose levels, with documented evidence of antitumor activity. This additional Phase I/II study seeks to evaluate GL-ONC1 administered repetitively every 4 weeks up to 4 cycles via infusion using an implanted catheter in the peritoneal cavity. In Phase I, patients will be individually assessed for safety and dose limiting toxicity. The study aims of Phase II portion are continued collection of safety information to better define the tolerability of GL-ONC1, as well as viral replication and the action or effect of GL-ONC1 in humans at the selected dose level and dosing schedule for future trials. Throughout both phases of the study, anti-tumor effects will be evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis
Study Start Date : February 2012
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Viral Infections

Intervention Details:
  • Biological: GL-ONC1
    A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.

Primary Outcome Measures :
  1. Determine safety of administering GL-ONC1 intraperitoneally by the evaluation of the number of patients experiencing Adverse Events (type, frequency, and severity) [ Time Frame: Change from baseline over 24 hours, on days 2, 3, 4,5,6, 7 post treatment (Cycle 1) and change from baseline for Cycles 2- 4 CX/Days 1, 2, 3, 5, 8 post-treatment. Each cycle is 4 weeks and treatment will occur for a total of 4 cycles. ]
    The safety of GL-ONC1 will be assessed by the evaluation of the type, frequency, and severity of adverse events (AEs), changes in laboratory tests (haematological, chemistry, urinary), immunogenicity and physical examination

Secondary Outcome Measures :
  1. Dose Level and Dose Schedule [ Time Frame: End of Phase I (at 18 mo.), at monthly treatments, and after study completion (expected at 36 mo.) ]
    Determination of recommended dose and schedule for phase II portion of trial and future investigations by analysis of safety and efficacy data

  2. Detection of Anti-tumor Activity [ Time Frame: Tumor imaging [pre-study, mid-term (Day 43), after last treatment (Day 106), for 1 year @ 12-week intervals for patients with stable disease/better); Tumor markers and peritoneal cytologies collected on average over 4 months ]
    Sampling of evidence of anti-tumor activity via standard imaging practices, viral delivery to tumor and normal cells, and immune response activity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of histologically or cytologically documented, advanced stage of peritoneal carcinomatosis that is refractory to standard therapy, exhibiting a likely survival of > 4 months as being judged clinically.
  2. Evidence of measurable disease.
  3. Age ≥ 18 years.
  4. ECOG (Eastern Cooperative Oncology Group Performance Status) ≤ 2.
  5. Required baseline laboratory data include:

    • Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.
    • Platelets ≥ 75 ×109/L
    • Haemoglobin ≥ 9.5 g/dL
    • Serum creatinine ≤ 2 × upper limit of normal(ULN)
    • Total Bilirubin ≤ 5 × ULN
    • AST/ALT ≤ 7.5 × ULN
    • Negative pregnancy test for females of childbearing potential
    • Serum albumin ≥ 2.5 g/dL.
    • If serum albumin level is < 2.5/dL,albumin substitution should take place until the threshold of ≥ 2.5 g/dL.
  6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, implantation of the indwelling peritoneal catheter, as well as the respective drainage procedures.
  7. All patients must agree to use highly effective contraception.

Exclusion Criteria:

  1. Patients exhibiting objective evidence at baseline of brain metastases are excluded from participating.
  2. Pregnant or breast-feeding women.
  3. Primary tumors and metastases to tissues/organs which, under clinical judgment, will likely hinder survival for at least the next 4 months.
  4. Patients with fever, any active immunosuppressive systemic infection or a suppressed immune system, including known HIV, as assessed within 14 days prior to study enrolment.
  5. Concurrent vaccination or immunotherapy for 28 days before study therapy and during study treatment.
  6. Patients on immunosuppressive therapy or with immune system disorders, including autoimmune diseases. Concurrent steroid use of not more than an equivalent of 20 mg/day prednisolone is allowed.
  7. Prior splenectomy.
  8. Previous organ transplantation.
  9. Fully therapeutic coagulation therapy that does not allow the intraperitoneal insertion of a permanent catheter.
  10. Patients with clinically significant dermatological disorders(e.g., eczema or psoriasis), any skin lesions or ulcers, any history of atopic dermatitis, or any history of Darier's disease (Keratosis Follicularis).
  11. Clinically significant cardiac disease (New York Heart Association, Class III or IV: see Appendix 10)
  12. Known allergy to ovalbumin or other egg products.
  13. Concurrent use of antiviral agents active against vaccinia virus.
  14. Prior gene therapy treatment or prior therapy with cytolytic virus of any type.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01443260

Layout table for location information
University Hospital Tuebingen
Tuebingen, Germany, D-72076
Sponsors and Collaborators
Genelux GmbH
Layout table for investigator information
Principal Investigator: Ulrich M. Lauer, Prof. Dr. med. University Hospital Tuebingen
Principal Investigator: Michael Bitzer, University Hospital Tuebingen
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Genelux GmbH Identifier: NCT01443260    
Other Study ID Numbers: Genelux - PO2
2010-022680-35 ( EudraCT Number )
First Posted: September 29, 2011    Key Record Dates
Last Update Posted: March 10, 2015
Last Verified: March 2014
Keywords provided by Genelux Corporation ( Genelux GmbH ):
oncolytic virus
Vaccinia virus
Genelux GmbH
peritoneal carcinomatosis
abdominal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Peritoneal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Abdominal Neoplasms
Neoplasms by Site
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Poxviridae Infections
DNA Virus Infections
Virus Diseases